表紙
市場調查報告書

著重癌症的液態切片:全球市場的預測 2023年

Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

出版商 BCC Research 商品編碼 860081
出版日期 內容資訊 英文 277 Pages
訂單完成後即時交付
價格
Back to Top
著重癌症的液態切片:全球市場的預測 2023年 Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023
出版日期: 2019年05月31日內容資訊: 英文 277 Pages
簡介

全球液態切片市場規模,預計從2018年的23億美元到2023年達到61億美元,其間為21.1%的年複合成長率。

本報告提供全球液態切片市場相關調查,全球市場的液態切片技術,應用,產業次區域概要,世界市場趨勢分析與預測,地區動態分析,及主要企業簡介等資訊。

第1章 簡介

第2章 摘要

第3章 概要

  • 簡介
  • 液態切片 vs. 傳統活體組織切片
  • 市場
  • 成長促進因素
  • 主要趨勢
  • 液態切片主要的發展
  • 產業

第4章 技術背景

  • 液態切片的生物標記
  • 癌症基因學
  • 侵入性產前檢查
  • 非侵入性產前檢查 (NIPT)
  • 循環腫瘤細胞 (CTC)
  • CTC工作流程
  • 液態切片 vs. 傳統活體組織切片
  • 癌症檢驗

第5章 液態切片的舉措

第6章 市場分析:各終端用戶

  • 簡介
  • 癌症應用
  • NIPT應用
  • 移植診斷應用

第7章 液態切片產業

  • 簡介
  • 先進定序設備產業
  • NGS設備產業
  • 第3代定序產業
  • 微滴式方式數位PCR產業
  • 靶向序列捕獲、放大產業
  • 單細胞DNA聚合酵素產業
  • 非侵入性產前檢查產業
  • CTC捕捉 & 檢測產業
  • 液態切片化驗產業

第8章 產業上收購、策略性聯盟

  • M&A
  • 收購
  • 策略性聯盟
  • 開發平台分析
  • 主要趨勢

第9章 液態切片市場

  • 成長促進因素
  • 液態切片市場:各應用領域
  • 液態切片市場:各生物標記類型
  • 液態切片市場:各分析平台
  • 液態切片市場:各分析目的
  • 地區市場
  • 非侵入性產前檢查市場
  • 癌症市場
  • 移植市場
  • 地區市場分析

第10章 專利檢討/新開發

  • 循環腫瘤細胞專利
  • 外吐小體專利
  • 無細胞DNA專利
  • 液態切片、定序相關專利的問題

第11章 企業簡介

目錄
Product Code: HLC238A

Report Highlights:

The global market for liquid biopsy should grow from $2.3 billion in 2018 to reach $6.1 billion by 2023 at a compound annual growth rate (CAGR) of 21.1% for the period of 2018-2023.

Noncancer as a segment of liquid biopsy market should grow from $1.9 billion in 2018 to reach $3.7 billion by 2023 at a CAGR of 14.1% for the period of 2018-2023.

Cancer as a segment of liquid biopsy market should grow from $411.7 million in 2018 to reach $2.4 billion by 2023 at a CAGR of 41.7% for the period of 2018-2023.

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report discusses several significant, large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments, droplet digital PCR (polymerase chain reaction), target enrichment, single-cell DNA polymerase, non-invasive prenatal testing (NIPT), fetal-cell NIPT, CTC (circulating tumor cell) capture and detection and liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/ early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia Pacific, Rest of the World).

Market data covers 2017, 2018 and 2023 (forecasted).

More than 175 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.

Report Includes:

  • 27 data tables and 70 additional tables
  • An overview of the global markets for liquid biopsy technologies, applications, industry subsegments
  • Analyses of global market trends with data from 2017 to 2018 and projections of compound annual growth rates (CAGRs) through 2023
  • Regional dynamics of the liquid biopsy diagnostics market covering North America, Europe, APAC and rest of the world covering other emerging economies
  • Discussion of major drivers, current trends and global outlook of liquid biopsy technologies, their growth potential and factors that influence the market
  • Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
  • Comparative study of liquid biopsy with conventional biopsy technologies and coverage of their respective biomarkers
  • Comprehensive company profiles of key market players within the industry, including Apocell Inc., Becton, Dickinson and Co., Clinical Genomics Technologies, Exact Sciences Corp. and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary

Chapter 3: Overview

  • Introduction
  • Liquid Biopsy vs. Traditional Biopsy
  • Markets
  • Forces Driving Growth
  • Key Trends
  • Key Developments in Liquid Biopsy
  • Industry

Chapter 4: Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Invasive Prenatal Testing
  • Non-invasive Prenatal Testing (NIPT)
  • Circulating Tumor Cells (CTCs)
  • CTC Workflow
  • Liquid Biopsy vs. Conventional Biopsy
  • Cancer Testing

Chapter 5: Liquid Biopsy Initiatives

  • Immunomonitor Consortium (2018)
  • Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program (2018)
  • Liquid Biopsies and Imaging for Improved Cancer Care (2018)
  • Precancer Atlas (2018)
  • TopMed (2017)
  • Blood Profiling Atlas (2016)
  • Human Cell Atlas (2016)
  • Population Sequencing Projects (2016)
  • Cancer-ID (2015)
  • Precision Medicine Initiative (2015)
  • Early Cancer Detection Consortium (2014)
  • CTC Trap Consortium (2012)
  • EpiFemCare (2012)
  • Single-Cell Research (2012)
    • Cambridge Single-Cell Analysis Core Facility
    • Harvard Medical School Single-Cell Core
    • Mayo Medical Genome Facility
    • National Center for Single-Cell Biology
    • Single-Cell Analysis Core
    • UC San Francisco Single-Cell Analysis Center
  • Worldwide Innovative Networking (WIN) Consortium (2010)
  • Next-Generation Single-Cell Analysis Program
  • Single-Cell Proteomics and Lipidomics Project

Chapter 6: Market Breakdown by End User

  • Introduction
  • Cancer Applications
    • Precision Medicine
    • Cancer Biomarker Status
    • Cancer Market Segments
  • NIPT Applications
  • Transplant Diagnostic Applications

Chapter 7: Liquid Biopsy Industry

  • Introduction
  • Advanced Sequencing Instruments Industry
  • NGS Instrument Industry
    • MiSeq
    • NextSeq
    • MiniSeq
    • ISeq 100
    • Ion Torrent
    • PromethIon
    • MinIon
    • GridION X5
  • Third-Generation Sequencing Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-cell DNA Polymerase Industry
  • Non-Invasive Prenatal Testing Industry
    • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry

Chapter 8: Industry Acquisitions and Strategic Alliances

  • Mergers and Acquisitions
  • Acquisitions
  • Strategic Alliances
  • Pipeline Analysis
  • Key Trends

Chapter 9: Liquid Biopsy Markets

  • Forces Driving Growth
  • Liquid Biopsy Market by Application
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Geographic Markets
  • Non-Invasive Prenatal Testing Market
  • Cancer Markets
    • Cancer Market by Disease Indication
    • Cancer Market by Analysis Purpose
    • Cancer Market by Biomarker Class
    • Cancer Market by Analysis Method
    • Breast Cancer Market
    • Colorectal Cancer Market
    • Hematological Cancer Market
    • Lung Cancer Market
    • Pan-Cancer Market
  • Transplant Markets
  • Regional Market Analysis

Chapter 10: Patent Review/ New Developments

  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA Patents
  • Liquid Biopsy and Sequencing-Related Patent Issues

Chapter 11: Company Profiles

  • ACCURAGEN INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES, INC.
  • AKADEUM LIFE SCIENCES
  • ALCEDIAG
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARCEDI BIOTECH APS
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • ATRECA INC.
  • AVIVA BIOSCIENCES
  • BAYLOR GENETICS
  • BECTON, DICKINSON AND CO.
  • BELLWETHER BIO INC.
  • BERRY GENOMICS CO. LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIOCORE CO. LTD.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOMARX INC.
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE LTD.
  • BIOVENDOR-LABORATORNI MEDICINA A.S.
  • BLUESTAR GENOMICS INC.
  • BOREAL GENOMICS
  • CANCER GENETICS INC.
  • CAREDX INC.
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CIRCULOMICS INC.
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • COLOR GENOMICS
  • CS GENETICS LTD.
  • CYGNUS BIOSCIENCES CO. LTD.
  • CYNVENIO BIOSYSTEMS INC.
  • CYTOTRACK APS
  • DATAR CANCER GENETICS LTD.
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIRECT GENOMICS CO. LTD.
  • DNA ELECTRONICS LTD.
  • DNALYTICS
  • DNANEXUS INC.
  • DOVETAIL GENOMICS LLC
  • ENVISION GENOMICS
  • EPIC SCIENCES INC.
  • EUROFINS SCIENTIFIC
  • EXACT SCIENCES CORP.
  • EXOSOME SCIENCES INC.
  • EXPEDEON AG
  • EZLIFE BIO INC.
  • FABRIC GENOMICS
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENEDX INC.
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETICS RESEARCH LLC
  • GENOMATIX GMBH
  • GENOMIC HEALTH INC.
  • GENOMONCOLOGY
  • GENOSPACE
  • GENEXOSOME TECHNOLOGIES INC.
  • GIGAGEN INC.
  • GOLDEN HELIX
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HELITEC
  • HELIX OPCO LLC
  • HTG MOLECULAR DIAGNOSTICS INC.
  • ILLUMINA INC.
  • IMMUNOVIA AB
  • INEX INNOVATIONS EXCHANGE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE DIAGNOSTICS LLC
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • KONINKLIJKE PHILIPS N.V.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • MAMMOTH BIOSCIENCES INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME LABS PVT. LTD.
  • MEDOMICS LLC
  • MENARINI SILICON BIOSYSTEMS SPA
  • MERCK KGAA
  • MOLECULAR HEALTH GMBH
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NANOVIEW BIOSCIENCES INC.
  • NATERA INC.
  • NAVERIS INC.
  • NEOGENOMICS LABORATORIES
  • NEW ENGLAND BIOLABS
  • NEW ONCOLOGY GMBH
  • NIPD GENETICS
  • N-OF-ONE INC.
  • NOVOGENE CO. LTD.
  • NUGEN TECHNOLOGIES INC.
  • NUPROBE INC.
  • NX PRENATAL INC.
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PANGAEA ONCOLOGY
  • PARADIGM DIAGNOSTICS INC.
  • PARSEQ LAB CO. LTD.
  • PATHWAY GENOMICS CORP.
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PIERIANDX
  • PORTABLE GENOMICS LLC
  • PRECIPIO INC.
  • PREDICINE INC.
  • PREMAITHA HEALTH PLC
  • PRENETICS
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RARECYTE INC.
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SCREENCELL
  • SEEKIN
  • SENGENICS LTD.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLERA GENOMICS INC.
  • SOPHIA GENETICS
  • SPERA MEDICAL
  • SPHERE FLUIDICS LTD.
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT. LTD.
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYSMEX INOSTICS GMBH
  • TAI DIAGNOSTICS INC.
  • TAKARA BIO INC.
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TRANSPLANT GENOMICS
  • TROVAGENE INC.
  • TWINSTRAND BIOSCIENCES
  • TWO PORE GUYS INC.
  • TYMORA ANALYTICAL OPERATIONS LLC
  • UBIQUITY GENOMICS INC.
  • VORTEX BIOSCIENCES
  • VELA DIAGNOSTICS
  • VOLITIONRX
  • VORTEX BIOSCIENCES
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy: Report Scope
    • Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2023
    • Table 4: Forces Driving Growth
    • Table 5: Key Trends in the Liquid Biopsy Market
    • Table 6: Liquid Biopsy Industry Subsectors
    • Table 7: Liquid Biopsy: Biomarker Classes
    • Table 8: Clinical Implications of CTCs
    • Table 9: Key Applications of Circulating Tumor DNA (ctDNA)
    • Table 10: Applications of ctDNA, CTCs and Exosomes
    • Table 11: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 12: Genomics-Based Oncology Workflow
    • Table 13: Prenatal Invasive Testing Technologies
    • Table 14: Invasive and Non-Invasive Prenatal Technologies
    • Table 15: Unique Challenges: CTC Capture and Analysis
    • Table 16: CTC Workflow
    • Table 17: Cell Differentiators
    • Table 18: Cell Isolation Technologies
    • Table 19: CTC-Isolating Markers
    • Table 20: CTC Sample Preparation Technologies
    • Table 21: Single-Cell Analysis Technologies
    • Table 22: Limitations of Conventional Biopsy
    • Table 23: Liquid vs. Traditional Biopsy
    • Table 24: Estimated Annual Solid Biopsy Procedures in the U.S.: Selected Cancers
    • Table 25: Main Risks: Needle-Based Tissue Biopsies
    • Table 26: Factors in Tissue Biopsy
    • Table 27: Liquid Biopsy Research and Development Programs, 2010-2018
    • Table 28: Single-Cell Core Research Facilities
    • Table 29: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 30: Personalized Medicine for Common Cancer Genetic Mutations
    • Table 31: Clinical Status of Cancer Biomarkers in Liquid Biopsy
    • Table 32: Cancer Liquid Biopsy Market Segments
    • Table 33: Reproductive Health Screening Applications
    • Table 34: Ethical Issues Associated with NIPT
    • Table 35: Transplant Diagnostic Applications
    • Table 36: Key Segments and Trends: Liquid Biopsy Industry
    • Table 37: Advanced Sequencing Industry Company Positioning
    • Table 38: End-to-End Sequencing Approaches
    • Table 39: Next-Generation Sequencing Instrument Companies
    • Table 40: NGS Instruments
    • Table 41: Benchtop and Handheld Sequencer Platforms
    • Table 42: 3GS Industry, by Tier Status
    • Table 43: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 44: Digital PCR Liquid Biopsy Industry
    • Table 45: Target Enrichment Industry
    • Table 46: Single-Cell DNA Polymerase Industry
    • Table 47: Major Companies Associated with the NIPT Industry
    • Table 48: Estimated Number of NIPT Assays, by Company, 2018
    • Table 49: Germany NGS-Based Non-Invasive Prenatal Diagnostic Companies, 2017
    • Table 50: NIPT Test Licensing, by Country
    • Table 51: Fetal Cell NIPT Industry
    • Table 52: CTC Separations Industry
    • Table 53: Liquid Biopsy Assay Industry: Company Focus
    • Table 54: NGS-Based Liquid Biopsy Market Differentiation
    • Table 55: Liquid Biopsy Industry: Mergers and Acquisitions of Key Players, 2016-2018
    • Table 56: Liquid Biopsy: Industry Acquisitions, January 2017 Through November 2018
    • Table 57: Liquid Biopsy: Strategic Alliances, January 2017 Through November 2018
    • Table 58: Liquid Biopsy: Pipeline Analysis, January 2017 Through December 2018
    • Table 59: Liquid Biopsy: Forces Driving Growth and Implications Through 2023
    • Table 60: Global Liquid Biopsy Market, by Application, Through 2023
    • Table 61: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
    • Table 62: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 63: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
    • Table 64: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
    • Table 65: Global Liquid Biopsy Market, by Region, Through 2023
    • Table 66: Global Market for Liquid Biopsy in NIPT Applications, by Analysis Purpose, Through 2023
    • Table 67: Global Market for Liquid Biopsy in NIPT Applications, by Risk Type, Through 2023
    • Table 68: Global Market for Liquid Biopsy in NIPT Applications, by Biomarker Class, Through 2023
    • Table 69: Global Market for Liquid Biopsy in NIPT Applications, by Analysis Method, Through 2023
    • Table 70: Limitations of Solid/Tissue Biopsy in Cancer Applications
    • Table 71: Low-Frequency Mutation Detection
    • Table 72: Global Market for Liquid Biopsy in Cancer Applications, by Disease Indication, Through 2023
    • Table 73: Five-Year Survival Rate for Ovarian Cancer
    • Table 74: NIH Liquid Biopsy Early Detection Initiative
    • Table 75: Molecular Thyroid Nodule Classifier Tests
    • Table 76: Global Market for Liquid Biopsy in Cancer Applications, by Analysis Purpose, Through 2023
    • Table 77: MRI and Liquid Biopsy Methods
    • Table 78: Early Detection Tissue of Origin Approaches
    • Table 79: Global Market for Liquid Biopsy in Cancer Applications, by Biomarker Class, Through 2023
    • Table 80: Global Market for Liquid Biopsy in Cancer Applications, by Analysis Method, Through 2023
    • Table 81: Global Market for Liquid Biopsy in Breast Cancer Applications, by Analysis Method, Through 2023
    • Table 82: Global Market for Liquid Biopsy in Colorectal Cancer Applications, by Analysis Method, Through 2023
    • Table 83: Global Market for Liquid Biopsy in Hematological Cancer Applications, by Analysis Method, Through 2023
    • Table 84: Global Market for Liquid Biopsy in Lung Cancer Applications, by Analysis Method, Through 2023
    • Table 85: Global Market for Liquid Biopsy in Pan-Cancer Applications, by Analysis Method, Through 2023
    • Table 86: Global Market for Liquid Biopsy in Transplant Applications, by Analysis Purpose, Through 2023
    • Table 87: Global Market for Liquid Biopsy in Transplant Applications, by Organ Type, Through 2023
    • Table 88: Transplant Procedures Performed in the United States, 2016 Through September 2018
    • Table 89: Global Market for Liquid Biopsy in Transplant Applications, by Analysis Method, Through 2023
    • Table 90: Global Market for Liquid Biopsy in Transplant Applications, by Biomarker Class, Through 2023
    • Table 91: Global Market for Liquid Biopsy in Cancer Applications, by Region, Through 2023
    • Table 92: Global Market for Liquid Biopsy in NIPT Applications, by Region, Through 2023
    • Table 93: Global Market for Liquid Biopsy in Transplant Application, by Region, Through 2023
    • Table 94: Patent Activity for Circulating Tumor Cells (CTCs), by Country/Region, 2008-2018
    • Table 95: Patent Activity for Exosomes, by Country/Region, 2008-2018
    • Table 96: Patent Activity for Cell-Free DNA (cfDNA) by Country/Region, 2008-2018
    • Table 97: Liquid Biopsy and Sequencing-Related Patent Disputes

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
    • Figure 1: Timeline of Liquid Biopsy Development
    • Figure 2: Molecular Applications of Biomarkers as Liquid Biopsy for Personalized Medicine
    • Figure 3: How Cancer Genomics Drive Liquid Biopsy
    • Figure 4: Clinical Applications of Liquid Biopsy for Precision Medicine
    • Figure 5: Shedding of Circulating Tumor Cells
Back to Top